Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV study of mulberry twig alkaloids tablets for type 2 diabetes
ChiCTR2400088362Phase 4Recruiting
- Sponsor
- Shanghai Sixth People's Hospital Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ramulus mori alkaloids in type 2 diabetes mellitus (T2DM), sponsored by Shanghai Sixth People's Hospital Peking Union Medical College Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Glycosylated hemoglobin at week 52 and Clinically significant changes in vital signs. Started Aug 2024; status: recruiting.
02
Drugs
ramulus mori alkaloids
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400088362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088362.